MedTrace Logo

Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

NCT06737354 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-04-30

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.

Conditions

Interventions

GENETIC

IVB103 Injection（Low dose）

Single intravitreal injection

GENETIC

IVB103 Injection（Intermediate dose）

Single intravitreal injection

GENETIC

IVB103 Injection（High dose）

Single intravitreal injection

Sponsors & Collaborators

  • NeoVec Biotherapeutics Inc.

    collaborator INDUSTRY

  • InnoVec Biotherapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2027-12-31
Completion
2031-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06737354 on ClinicalTrials.gov